Inno-206
Fallopian Tube Neoplasms
Eli Lilly and CompanyPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Fallopian Tube Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Eli Lilly and Company | Phase 3 | BB |
Trabectedin Janssen Research & Development, LLC | Phase 3 | B |
Pembrolizumab Seagen, a wholly owned subsidiary of Pfizer | Phase 3 | B |
Mirvetuximab Soravtansine Eli Lilly and Company | Phase 3 | B |
Hycamtin Eli Lilly and Company | Phase 3 | B |
View all 39 →
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →